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The occurrence of pharmaceuticals and per-
sonal care products (PPCPs) in the environ-
ment has received growing attention since the
1980s. The major issues associated with the
origins and occurrence of these chemicals in
surface, subsurface, and drinking waters (as
well as what little is known about the potential
effects on nontarget species) have been cap-
tured in a number of reviews, books, and pro-
ceedings, examples of some recent ones of
which include Daughton (2001a), Daughton
and Jones-Lepp (2001), Daughton and Ternes
(1999), Heberer (2002); see also Kümmerer
(2001), Servos et al. (2002), and the entire spe-
cial issue of Toxicology Letters (2002). The
most comprehensive target-monitoring study
ever performed was completed by the U.S.
Geological Survey (USGS) (Kolpin et al.
2002). Many of these materials (and more) are
accessible from the U.S. Environmental
Protection Agency (U.S. EPA) website devoted
to the topic of PPCPs in the environment
(Daughton/U.S. EPA 2002a).
This article is the ﬁrst of a two-part exam-
ination of the many facets of a little-discussed
but very important aspect of the overall issue
of PPCPs as environmental pollutants: pollu-
tion prevention. In light of the fact that trace
residues from this large, diverse galaxy of
sometimes highly bioactive chemicals gain
entry to the environment simply through
their use and disposal, and regardless of what
little is known regarding the consequences for
ecologic or human health (Daughton 2001a;
Daughton and Ternes 1999), a wide spec-
trum of actions could be taken to minimize
or eliminate the continued environmental
disposition of PPCPs. Significantly, these
actions toward pollution prevention (e.g.,
source reduction/control) hold the potential
at the same time for beneﬁcial human health
consequences unrelated to the occurrence of
PPCPs as pollutants. In this article I focus on
those aspects of source control/reduction that
reside under the control of the health care
industry (further up the chain of events
involved with a drug’s cradle-to-grave disposi-
tion). In part II (Daughton 2003), I address
those activities tied more closely to the end
user (e.g., the patient) and issues associated
with drug disposal/recycling. In this article I
also present some of the background and con-
text for why pollution prevention is a topic
worth considering for PPCPs; in part II, I
make specific suggestions and recommenda-
tions centering more on end use, present rec-
ommendations for further research, and pose
some considerations regarding the future.
With a focus on pollution prevention
(e.g., source elimination or minimization) via
voluntary actions as an alternative to conven-
tional pollution control via prescribed stan-
dards, this mini-monograph is intended as a
companion piece to the review published in
Environmental Health Perspectives (Daughton
and Ternes 1999) that focused primarily on
the origins and environmental occurrence of
PPCPs together with an introduction to what
little was known at that time about the
potential for adverse ecologic effects.
One of my major objectives in this mono-
graph is to generate an active dialog or debate
across the many disciplines that must become
actively involved to design and implement a
successful approach to life-cycle stewardship of
PPCPs—an approach that not only minimizes
their potential to affect the environment but
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Since the 1980s, the occurrence of pharmaceuticals and personal care products (PPCPs) as trace
environmental pollutants, originating primarily from consumer use and actions rather than manu-
facturer efﬂuents, continues to become more ﬁrmly established. Although PPCPs typically have been
identiﬁed in surface and ground waters, some are also undoubtedly associated with solid phases such
as suspended particulates, sediments, and sewage sludges, despite their relatively high afﬁnity for
water. Often amenable to degradation, their continual introduction to waste-receiving waters results
from their widespread, continuous, combined use by individuals and domestic animals, giving
PPCPs a “pseudo-persistence” in the environment. Little is known about the environmental or
human health hazards that might be posed by chronic, subtherapeutic levels of these bioactive sub-
stances or their transformation products. The continually growing, worldwide importance of fresh-
water resources, however, underscores the need for ensuring that any aggregate or cumulative
impacts on (or from) water supplies are minimized. Despite the paucity of effects data from long-
term, simultaneous exposure at low doses to multiple xenobiotics (particularly non-target-organism
exposure to PPCPs), a wide range of proactive actions could be implemented to reduce or minimize
the introduction of PPCPs to the environment. Most of these actions fall under what could be envi-
sioned as a holistic stewardship program—overseen by the health care industry and consumers alike.
Signiﬁcantly, such a stewardship program would beneﬁt not just the environment; additional, collat-
eral beneﬁts could automatically accrue, including reducing consumers’ medication expenses and
improving patient health and consumer safety. In this article, the ﬁrst of a two-part mini-monograph
describing the “green pharmacy,” I focus initially on the background behind the imperative for an
ecologically oriented stewardship program for PPCPs. I then present a broad spectrum of possible
source control/reduction actions, controlled largely by the health care industry, that could minimize
the disposition of PPCPs to the environment. This two-part mini-monograph attempts to capture
cohesively for the ﬁrst time the wide spectrum of actions available for minimizing the release of
PPCPs to the environment. A major objective is to generate an active dialog or debate across the
many disciplines that must become actively involved to design and implement a successful approach
to life-cycle stewardship of PPCPs. Key words: cradle-to-cradle stewardship, drugs, environmental
pollution, green pharmacy, pollution prevention. Environ Health Perspect 111:757–774 (2003).
doi:10.1289/ehp.5947 available via http://dx.doi.org/ [Online 12 December 2002]
Green Pharmacy Mini-Monographalso could collaterally improve medical health
care outcomes for consumers and reduce
health care costs. Although the onus for envi-
ronmental stewardship rests primarily with the
larger health care community (including the
consumer), almost no discussion of the overall
issue has taken root in the medical literature
(Daughton 2002a). A cohesive, scientifically
sound set of guiding principles could be
adopted by the industries involved with manu-
facturing, packaging, distribution, and pur-
veyance of PPCPs—principles that would also
inﬂuence or guide consumer actions. By focus-
ing on developing an industry consensus and
cultural mindset toward holistic environmental
responsibility rather than relying on compli-
ance to regulations, all sectors of society could
play integral, productive roles in striving for a
sustainable environment.
Opportunity for Caution:
Toxicity Out of Context
Although PPCPs are often considered “emerg-
ing” pollutants, it is reasonable to surmise that
the occurrence of PPCPs in waters is not a new
phenomenon. Their occurrence has become
more widely evident since the 1990s only
because continually improving chemical analy-
sis methodologies have lowered the limits of
detection for a wide array of xenobiotics in
environmental matrices. There is no reason to
believe that any given PPCP has not had the
potential to ﬁnd its way into the environment
since the date of its introduction to com-
merce—or even from the date it was ﬁrst used
for experiments or clinical trials.
Most current approaches to pollutant
tracking center on the small subset of anthro-
pogenic (and some naturally occurring) toxi-
cants in the environment. Signiﬁcantly, these
“conventional” pollutants do not necessarily
serve as surrogates representing the extremely
wide spectrum of modalities by which toxi-
cants can adversely affect organisms. That
regulated pollutants account for such a small
fraction of potential chemical stressors begs a
question that can be formulated from a
notion often attributed to Einstein, para-
phrased as “Not everything that can be
counted counts, and not everything that
counts can be counted.” A corollary can be
derived from this for environmental monitor-
ing: “Not everything that can be measured is
worth measuring, and not everything worth
measuring is measurable.” The spectrum of
pollutants typically identified in an environ-
mental sample represents an unknown por-
tion of those actually present (possibly very
small), and they are of unknown overall risk
signiﬁcance (Figure 1).
Because of the extraordinary complexity of
both exposure and outcome, toxicologists usu-
ally are forced to look at cause–effect issues “out
of context”: The historic ramiﬁcation has been
to consider exposure solely as a function of a
single toxicant or a very limited set of chemical
stressors. The overall picture, however, is com-
plicated not just by the large universe of po-
tential toxicants to which an organism can
normally be exposed at any point (or period) of
time but also by the host of other variables such
as exposure level, exposure route (e.g., dermal,
enteral, pulmonary), exposure timing (windows
of vulnerability, e.g., developmental stage),
prior exposure history, prior exposure duration
(e.g., acute—short-term, sequential, intermit-
tent, episodic—or chronic), nutrition, age, sex,
genetics, and nonchemical costressors (tempera-
ture, physical/metabolic stress, noise, electro-
magnetic radiation, pathogens). All these factors
determine an organism’s historic “exposure tra-
jectory,” which in turn determines its current
health status and sets the stage for the outcome
of current exposure (vulnerability vs. resistance
to homeostasis perturbation). With science’s
limited understanding of this complex,
dynamic interplay of multiple factors, risk
assessment is necessarily restricted to assessing
the ramifications of potential adverse toxic
events without the larger holistic perspective.
A convenient shorthand term that cap-
tures the complete context of an organism’s
cumulative exposure to chemical stressors does
not exist. One possibility offered here is “toxi-
cant–totality–tolerance–trajectory” (the “4Ts”;
see Daughton/U.S. EPA 2003a), which
accounts for an organism’s complete exposure
time line (a trajectory described by prior mul-
tidimensional exposure history) and the fact
that a major objective of all organisms is to
maintain homeostasis (in the face of continual
perturbation by stressors). Homeostasis can be
maintained only within the tolerance bounds
for the organism’s biochemical defensive
repertoire. So the 4Ts describe the hypotheti-
cal overall true risk as reflected by the sum
total of exposure to all toxicants (anthro-
pogenic and naturally occurring) throughout
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Figure 1. Limitations and complexities of environmental chemical analysis. TIC, tentatively identified
compound.the historical multidimensional space and
trajectory of all other exposure variables. A key
aspect to this concept is the critical state deter-
mined by the 4Ts—the state at which an
additional single exposure event can result in
an adverse effect.
The documented occurrence of PPCPs in
the environment may or may not eventually
have any implications regarding either ecologic
or human health—primarily because their
known concentrations are so low [nanograms
per liter (parts per trillion) to micrograms per
liter (parts per billion)]. The issues associated
with potential ecologic effects in particular can-
not be resolved until aquatic and computa-
tional toxicologists (for an overview of
computational toxicology, see Bradley 2002)
begin to evaluate the effects on nontarget
organisms by simultaneous, long-term expo-
sure to multiple PPCPs at low doses and to
assess the signiﬁcance of cumulative exposure
to PPCPs sharing the same biochemical mech-
anism of action (MOA). Indeed, therapeutic
doses for target organisms (which are often
many orders of magnitude higher than dis-
solved waste concentrations) may not be rele-
vant benchmarks against which to assess risks
to nontarget species. Furthermore, environ-
mental monitoring tends to focus on concen-
trations of PPCPs dissolved in water (because
of their water solubility). This emphasis, how-
ever, could underestimate environmental loads
by unknown magnitude because of sorption to
suspended particulates, sediments, or sewage
biosolids; this could prove critically signiﬁcant
regarding interface phenomena and lead to
higher than projected exposure levels (e.g.,
exposure of microorganisms to antibiotics).
Given the ever-expanding universe of
receptors targeted for drug action, the futility
of attempting to assess environmental effects
using a chemical-by-chemical approach
(indeed, the traditional approach has relied
only on lists of preselected, individual chemi-
cals) becomes clearer as advances in drug
design continue. Instead, the focus could be
directed to understanding the ramiﬁcations of
entire classes that share a common MOA (or
common physiologic or behavioral end
point)—because of the probability of cumu-
lative exposure. Delineating the total envi-
ronmental burden of chemicals sharing a
particular MOA could be the objective
instead of targeting speciﬁc chemicals for reg-
ulation. First, however, those MOAs or cellu-
lar processes that pose inherent risks would
have to be identiﬁed and prioritized, includ-
ing significant effects or perturbations to
homeostasis that are a) unique to each thera-
peutic class (e.g., resistance selection for
antibiotics) and b) mediated via biochemical
features and pathways that are evolutionarily
conserved across taxa and are elicited by many
therapeutic classes (e.g., efﬂux pumps, cellular
stress protein response, apoptosis, specific
signaling pathways). Many of these same toxi-
cologic issues are discussed in a recent
overview (WHO 2002a) of endocrine-dis-
rupting compounds (EDCs), a small subset of
which are PPCPs; an EDC is an exogenous
substance that “alters function(s) of the
endocrine system and consequently causes
adverse health effects in an intact organism,
or its progeny, or (sub)populations” (WHO
2002a). Although the topics of PPCPs and
EDCs intersect only partly, they share some
controversial issues.
A critical aspect of determining the signiﬁ-
cance of MOAs must be factored into this
process. MOAs that lead directly to adverse
effects are not the only consideration—or,
paradoxically, not even necessarily the most
important. Chemicals that have no inherent
toxicity of their own but rather potentiate the
toxicity of others might contribute signiﬁcantly
to risk. Examples include inhibitors of efﬂux
pumps and of microsomal oxidases (Daughton
2001a; Daughton and Ternes 1999; Epel and
Smital 2001). Finally, arguing against the util-
ity of MOA-directed risk assessments are two
factors: Many drugs have multiple MOAs
(these are sometimes referred to as “dirty”
drugs), large numbers of which yet remain to
be identiﬁed. Further, gross, within-class end-
point differences are known to exist for certain
drugs; for example, some selective serotonin
reuptake inhibitors (a class of antidepressants)
have extremely potent effects on shellfish
reproductive behavior, whereas others have
almost no effect (Daughton and Ternes 1999;
Fong 2001).
Regardless of the risks that might be posed
by the current generations of PPCPs, the fact
that many members of this large, diverse uni-
verse of bioactive chemicals have the demon-
strated potential to enter the environment
provides the rare opportunity to investigate
proactively whether each of the myriad new
drugs under development poses adverse risks
to the environment (or humans). This knowl-
edge essentially affords us the luxury of an
early warning to direct more attention to
potential, unintended ramiﬁcations of intro-
ducing new PPCPs to commerce. It gives us
the advance opportunity to be watchful
regarding the future introduction to com-
merce of drugs designed with completely new
mechanisms of action and ever-increasing
biochemical potencies.
Nonetheless, many actions can be taken
in the shorter term to minimize the introduc-
tion of PPCPs to the environment. These rec-
ommendations and suggestions are the
subject of this mini-monograph. The ideas
presented here are based largely on the man-
ner in which medical care (which includes
pharmaceutical use) is conducted in the
United States and to lesser degrees in Canada,
Western Europe, and Australia. The wide
range of issues and suggestions presented here
might have no relevance to other parts of the
world. Also, the major focus of this mini-
monograph is a survey of the many avenues
available for reducing the controllable intro-
duction of PPCPs to the environment; I do
not address the many issues (especially the
potential for adverse effects) associated with
the unintended, uncontrollable excretion of
PPCPs and their metabolites into the envi-
ronment (an issue that can be addressed via
engineering “end-of-pipe” controls).
Fragmentation of Science
The large number of disciplines of science and
other professions that must be integrated to
address the many facets of PPCPs as pollu-
tants drives home the importance of cross-
communication among disparate disciplines.
Unfortunately, the fragmentation of science
(driven by specialization) is a problem that
continues to grow (Daughton 2001b, 2002b).
In this mini-monograph I attempt to weave
together many facets involved with preventing
environmental pollution by PPCPs. In doing
so, I address two objectives. First is an effort to
bring together the limited and fragmented lit-
erature that exists from the diverse ﬁelds and
interwoven aspects involved with approaches
for reducing the introduction of pharmaceuti-
cals to the environment—in the face of what
little is known about possible risks that might
be associated with these bioactive substances
in the environment. Second is an attempt to
delineate some of the major actions that could
be taken to minimize the introduction of
drugs to the environment—actions that could
be implemented with little planning, those
that would require major attention by the
numerous agencies involved with a patchwork
of laws and regulation of drug recycling and
disposal, and those that would require further
research and development. A major motive for
this mini-monograph is to foster an awareness
of the many complexities involving this
emerging issue—to present a wider perspective
for and appreciation of the larger literature.
Although recognizing the importance of in-
depth, critical reviews (Daughton 2001b,
2002b), I do not attempt to review compre-
hensively the many pertinent subjects or
aspects, but rather to cite some key references
so that those interested in particular aspects
can gain faster entry to a literature that is often
difﬁcult to locate. Most of the literature cov-
ered in this mini-monograph has never been
synthesized into a uniﬁed “message” or under-
standing. The literature on pharmaceuticals
encompasses a number of ﬁelds that are infre-
quently visited by environmental scientists.
Likewise, those involved in medical science
and health care practice are not fully informed
of the environmental issues and consequences
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disparate fields together here because much
could be gained by their cross-collaboration.
Engaging the Public
The topic of PPCPs as pollutants has captured
much attention from the press (Daughton/
EPA 2002b), and its visibility in the public is
marked by its introduction to educational cur-
ricula (from elementary school through col-
lege) and to the popular press (e.g., Buhner
2002). The public, educators, and students
have expressed much interest in the topic
because they can identify easily with its pri-
mary origin, which embodies the interconnect-
edness of humans and the environment—the
occurrence of PPCPs in the environment mir-
rors the intimate, inseparable, and immediate
connection between the diffuse actions and
activities of individuals and their environment
(Daughton 2001a; Daughton/U.S. EPA
2002a). PPCPs owe their origins in the envi-
ronment to their worldwide, universal, fre-
quent, and highly dispersed but cumulative use
by multitudes of individuals. Although the
public has long understood that individual
actions and activities are partly responsible for
terrestrial and air pollution (obvious examples
being litter and vehicle exhaust), public con-
nection with water pollution usually remains
lost in the perception that industry and agricul-
ture are the primary sources, not consumerism
and personal activities. This misconception is
illustrated by the underappreciated fact that of
the petroleum introduced to North American
oceans each year, about 85% comes from the
seemingly minuscule actions of individuals, not
large oil spills and pipeline leaks [National
Research Council (NRC) 2002a]. The strong
interest expressed by the public in the topic of
PPCPs grants scientists, educators, and policy
makers a rare opportunity to engage con-
sumers in learning about the environment
and the many actions they can take as indi-
viduals to improve overall ecologic and
human health. Indeed, the critical importance
of involving the public in scientific debates
and decision making for creating sustainable
communities is becoming more widely recog-
nized (NCSE 2001).
Advance Warning
With regard to assessing environmental risk
associated with PPCPs as pollutants, the sci-
ence to date has focused on the issues of envi-
ronmental sources and occurrence—primarily
chemical identities and concentrations in
waters and, to a much lesser degree, sewage
sludge. Newer occurrence data continue to be
published by researchers in Europe, Canada,
and the United States. One of the objectives of
the ﬁrst-ever U.S. national reconnaissance of
“emerging pollutants” in waters, conducted by
the USGS, was to establish baseline occurrence
data (Kolpin et al. 2002; USGS 2002). Some
further perspective on the USGS study is
important, however. The PPCPs documented
to occur in U.S. surface waters probably repre-
sent but a fraction of all those that actually
occur (because the USGS monitoring study,
like all monitoring studies, used a target-based
approach, where only a limited number of
compounds must be preselected for monitor-
ing). Whether the potential for human health
or ecologic effects from this subset of PPCPs is
eventually demonstrated is largely irrelevant.
More important, these occurrence data
demonstrate the potential for any consumer-
use chemical to enter the environment. This
foresight provides the opportunity to watch for
the future introduction to commerce of drugs
possessing totally new mechanisms of action
and ever-increasing biochemical potencies.
We can expect drug use to continue to
expand and increase because of a conﬂuence of
drivers: increased per capita consumption,
expanding population, expanding potential
markets (partly due to mainstream advertis-
ing/marketing), patent expirations (shift to less
expensive generics), new target age groups,
inverting age structure in the general popula-
tion, and new uses for existing drugs. Old
therapeutics are being used not just for addi-
tional clinical conditions (those for which they
were not originally developed) but also for
nondisease states—for example, medical
manipulation or alteration of personality traits
and satisfaction of certain social needs—
referred to as “cosmetic pharmacology.”
Limitations of Guidelines for
Environmental Risk
Assessments
Our ability to assess any risks that might be
posed to ecologic or human health by PPCPs
in the environment is hampered greatly by the
profound lack of relevant toxicologic informa-
tion, especially for the aquatic environment,
which tends to be the ultimate sink for these
predominantly nonvolatile, amphiphilic com-
pounds (although terrestrial exposure can
occur when sewage sludge with sorbed or
occluded PPCPs is applied to land) (Daughton
and Ternes 1999; NRC 2002b). For example,
in the United States, environmental assess-
ments for approving new drug applications
are required by the U.S. Food and Drug
Administration (FDA) only when the concen-
tration of a drug predicted to enter the aquatic
environment [expected environmental concen-
tration (EEC) or predicted environmental con-
centration (PEC), as used in Europe] would be
1 µg/L (1 ppb) or greater (U.S. DHHS 1998).
The FDA’s historical toxicity data for standard
aquatic tests demonstrate no conventional
effects at concentrations lower than 1 ppb (also
see regulatory discussions in Velagaleti and Gill
2001 and Velagaleti et al. 2002). In contrast,
the European Agency for the Evaluation of
Medicinal Products (EMEA 2001) has pro-
posed a trigger value of 0.01 µg/L (10 ppt) (see
discussion in Straub 2002). Regardless of the
actual value, however, the scientiﬁc validity of
these trigger approaches has been questioned
(e.g., CSTEE 2001), an issue stemming pri-
marily from the dearth of toxicologic informa-
tion on nontarget species. Regardless of
whether trigger values may be used, three
major additional factors are not accounted for
in any approach that uses “predicted” environ-
mental concentrations (i.e., EEC or PEC);
each factor is discussed in turn below.
Ramiﬁcations of geographic variability in
drug use. Calculation of PECs assumes a uni-
form geographic usage. In practice, however,
environmental occurrence is a function of the
local prescribing practices and usage customs
and the conﬂuence of hospitals (whose use of
drug types differs from that of the general
community). Although PPCP production/use
figures are largely confidential, recent data
from the first study ever published on geo-
graphic variation (across the United States) of
prescription drug use (Express Scripts 2001)
show that at least for some drugs, regional
preferences in use can vary by severalfold or
more. The types of drugs (and dosages) can
vary signiﬁcantly from municipality to munic-
ipality, county to county, region to region,
and country to country—largely as a function
of age structure of the populations and of pre-
scribing customs. This means that for highly
populated metropolitan areas with use of a
particular drug exceeding what would be
expected by a uniform distribution, the actual
environmental concentration (EEC or PEC)
could be higher than predicted.
Unaccounted sources. A variety of largely
undetectable, alternate sources for PPCPs
(other than legal sales through approved mar-
ket channels) contribute to overall use and are
not accounted for in EEC or PEC calculations.
Further complicating matters is that prescrip-
tion numbers and over-the-counter (OTC)
sales are only a rough measure of a drug’s use
because they account for just a portion of the
overall use. Physician samples (drugs that are
intended not to be sold but rather to promote
the sale of a drug), the resale “diversion mar-
ket,” black market sales, free trial offers by
manufacturers, and the little-publicized “pre-
scription drug patient assistance programs”
sponsored by the pharmaceutical industry (e.g.,
see links at DisabilityResources.org 2002) are
other, perhaps substantial, sources that are dif-
ﬁcult to account for. As an example, the sales
of drugs via the Internet may incur a substan-
tial, unregulated import of unknown quantities
of drugs from foreign countries; Internet sales
continue to increase and thus pose a concern to
the U.S. FDA (2002a) in terms of consumer
health. Countries also vary as to whether a
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OTC; this could be signiﬁcant for those drugs
that have the potential to be transported across
geographic boundaries.
Interactions. Exposure to just a single
toxicant at a time is most likely an extraordi-
narily rare event, especially in the aquatic
domain. Exposure is more likely a routine
multidimensional occurrence involving mul-
tiple chemical stressors with dynamic spatial
and temporal components and whose out-
comes have a strong dependency on prior
exposure history (the 4Ts). The current prac-
tice of risk assessment considers a single stres-
sor at a time, and if the PEC for the single
stressor is below the “no effect concentra-
tion” (which is a direct reﬂection solely of the
select few of the countless end points that
happen to be selected), further assessment is
usually deemed unnecessary. This approach
clearly relies on stressors acting in sequence
and independently (i.e., no interactions), but
aggregate and cumulative exposure may play
signiﬁcant roles (Figure 2).
In the final analysis, maximum PECs
should eventually be corroborated through
more extensive monitoring of all relevant envi-
ronmental compartments—the only way to
verify whether predicted concentrations agree
with reality. One way to collect sufﬁcient data
would be through a program such as the U.S.
EPA Office of Water’s Drinking Water
Contaminant Candidate List, which is admin-
istered under the U.S. EPA’s Unregulated
Contaminant Monitoring Rule (U.S. EPA
Ofﬁce of Water 2002).
PPCPs in the Environment and
Their Control
Sources. From the patterns that have emerged
in the published occurrence data, it is now
clear that all municipal treated sewage (unless
subjected to advanced wastewater treatment
technologies, e.g., reverse osmosis and granular
activated carbon)—regardless of location—will
contain PPCPs. The issue is not unique to any
particular municipal area. Each geographic area
will differ only with respect to the types, quan-
tities, and relative abundances of individual
PPCPs. Several major sources contribute to the
introduction of both licit and illicit drugs to
the environment (Daughton/U.S. EPA
2002c). The major three are probably excre-
tion, washing, and purposeful disposal. These
three sources most likely feed into municipal
waste systems and storm runoff (e.g., sanitary
or combined sewers), and to a lesser but signiﬁ-
cant degree are discharged directly to surface
waters via “straight-piping.” Waste discharged
to engineered systems is subjected to various
levels of treatment-technology sophistication
before discharge to receiving waters. PPCPs,
however, display a broad range of removal
efficiencies by waste and water treatment
technologies; some travel through sewage
treatment facilities with only minor reduc-
tions in concentration (the antiepileptic car-
bamazepine is but one example) (Daughton
and Ternes 1999; Heberer 2002). Also, some
minor overall sources could potentially play
signiﬁcantly large local roles. One is cemeter-
ies, which could provide a source of PPCPs to
the subsurface (Daughton 2003).
The continual input of PPCPs to the
aquatic environment via sewage can impart a
persistence-like quality to those compounds
that otherwise possess little inherent chemical
stability in the environment (Daughton and
Ternes 1999) because new molecules replenish
those that are being removed; these chemicals
can be referred to as “pseudo-persistent” pollu-
tants (Daughton 2002a). The full extent,
magnitude, and ramiﬁcations of their presence
in the aquatic environment, however, are
largely unknown. The two largest unknown
domains in toxicology, which are centrally ger-
mane to PPCPs as environmental pollutants,
are the signiﬁcance of a) chronic, multigenera-
tional, low-dose exposure [i.e., nanomolar to
picomolar (below parts per billion/parts per
trillion), a common concentration range for
PPCPs in waters] and b) simultaneous expo-
sure to multiple stressors. Both of these are
complicated further by each chemical’s per-
haps being in a constant state of ﬂux in both
absolute and relative abundance. The occur-
rence differences of PPCPs in raw sewage are a
function of a) local prescribing and use cus-
toms, b) conﬂuence of hospitals, c) state poli-
cies and customs regarding disposal of unused
PPCPs, and d) local manufacture and use of
illicit and abused drugs. For surface and
ground waters, the differences are a function
of a) whether any treatment technologies are
employed (straight-piping, malfunctioning
septic systems, overflow events), b) types of
treatment technologies employed (for sewage,
potable water, or reinjection waters), and
c) local/seasonal fluctuations in biophysico-
chemical transformation potential (e.g., biode-
gradation, photolysis, sediment/particulate
sequestration).
Key importance of water resources: impact
of untreated sewage. Regardless of whether the
efficiencies of waste or drinking water treat-
ment approaches can be improved, large vol-
umes of untreated wastewater are discharged
to surface waters each year. The release of
PPCPs into the environment would be maxi-
mized by the release of raw sewage. Sources of
raw sewage in the United States released to
streams, lakes, estuaries, oceans, and ground-
water are responsible for high but largely
unknown volumes: a) combined sewer over-
flows (CSOs), which contribute more than
4 × 1012 L/year [CSOs handle rainwater
runoff, domestic sewage, and industrial waste-
water, and are designed to discharge untreated
sewage during adverse storm events (U.S. EPA
Office of Wastewater Management 2002a)];
b) sanitary sewer overflows (severe weather,
system malfunction, improper system opera-
tion/maintenance); c) leakage from sewage
transport infrastructure (sewer pipe cracks
caused by tree roots and defective/collapsed
pipes); d) failing septic systems; e) unpermit-
ted privies; and f) straight-piping.
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Figure 2. Contributions of different chemicals to the Risk Cup, which shows the differences between the
various exposure scenarios. The Risk Cup presents a particular perspective of the ﬁrst three of the four
dimensions of the 4Ts (toxicant, totality, tolerance) but does not capture the fourth (trajectory).
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Synergism?Repair of existing sewage and water han-
dling infrastructure in the United States will
require huge resources. The American Society
of Civil Engineers’ 2001 Report Card for
America’s Infrastructure (ASCE 2001) assigned
nationwide grades of “D” for both drinking
water and wastewater infrastructures. More
than $20 billion annually is the estimated
need for rectifying the nation’s degenerating
water/waste infrastructures.
If PPCPs eventually prove to be an envi-
ronmental concern, it is not known whether
sewage treatment facilities could even be cost-
effectively modified to reduce emissions—
especially given the huge costs associated with
reestablishing and maintaining their original
performance. Ultimately, source control (pol-
lution prevention) aimed at disposal practices
as well as actual therapeutic use may prove
more effective. The remainder of this article
and all of part II (Daughton 2003) present
ideas regarding the broad spectrum of activi-
ties that could be encompassed by pollution
prevention.
Pollution Prevention
Regardless of the outcome of the toxicologic
significance of PPCPs for ecologic systems
(including humans), and regardless of the
progress that can be made with respect to
improving waste or water treatment technolo-
gies, a wide variety of actions can be initiated
in the near term to minimize the introduction
of PPCPs (as well as other consumer-oriented
xenobiotics) to the environment and thereby
reduce the potential for emerging risks or
risks that have yet to be gauged or character-
ized. These proactive actions span a wide spec-
trum of disciplines and serve as the focus for
this mini-monograph, a focus that is driven by
four of the 10 goals that formed the basis of the
U.S. EPA’s (2000) Strategic Plan—Goal 2
(Clean and Safe Water), Goal 4 (Preventing
Pollution and Reducing Risk in Communities,
Homes, Workplaces, and Ecosystems), Goal 5
(Better Waste Management, Restoration of
Contaminated Waste Sites, and Emergency
Response), and Goal 8 (Sound Science—
Improved Understanding of Environmental
Risk, and Greater Innovation to Address
Environmental Problems) (U.S. EPA 2000). In
addition, one of the primary goals of the U.S.
EPA’s Ofﬁce of Research and Development is
to identify and foster investigation of previ-
ously “hidden” or potential environmental
issues/concerns before they become critical
ecologic or human health problems—pollu-
tion prevention (e.g., source elimination or
minimization) being preferable to remedia-
tion or restoration (so as to minimize both
public cost and human/ecologic exposure).
An important consequence of reducing
the introduction of PPCPs to the environ-
ment is that a wide range of other benefits
could accrue to both consumers and industry.
By addressing the environmental issues associ-
ated with PPCPs as environmental contami-
nants, in most respects substantial collateral
improvements to health care could also be
achieved. These are highlighted in various
sections of both parts I and II of this mini-
monograph. Benefits to consumers could
include reduced health care costs partly as a
result of a more efﬁcient and safe administra-
tion of all chemicals used in health care.
Environmental Surprise and
the Precautionary Principle
A proactive approach to dealing with issues
posing unknown or unpredictable conse-
quence is rooted in the concept of “surprise”
in environmental systems. This concept was
perhaps originally formalized by ecologist
Crawford S. (Buzz) Holling in the early
1970s. “Surprise” occurs when 
causes turn out to be sharply different than was
conceived, when behaviors are profoundly unex-
pected, and when action produces a result oppo-
site to that intended—in short, when perceived
reality departs qualitatively from expectation.
(Holling 1986, p. 294) 
Environmental surprise occurs when the ulti-
mate hazards differ from those that were
anticipated. Further discussion is provided by
Schneider and Turner (1994).
In Holling’s view, “resilience” may enable
an ecosystem to return to a steady state after
being subjected to an unusual event (or an
ongoing succession of cumulative events)
denoted as being a surprise. But the state to
which it reverts may be different—in other
words, a discontinuous change is effected. The
ramiﬁcations of subtle perturbations to com-
plex systems such as ecosystems have been dis-
cussed in many forums [sometimes called the
“butterﬂy effect,” where the ﬂapping of a but-
terfly’s wings in one geographic locale may
make the difference sometime in the future
between calm and unstable weather in another
locale (Gleick 1987)]. Edward Lorenz (an MIT
meteorologist who laid the groundwork for
what would become known as “sensitive
dependence on initial conditions,” a prime fac-
tor in “deterministic chaos,” later known as the
butterﬂy effect) concluded that the sensitivity
to initial conditions 
implies that two states differing by imperceptible
amounts may eventually evolve into two consider-
ably different states. If, then, there is any error
whatever in observing the present state—and in
any real system such errors seem inevitable—an
acceptable prediction of an instantaneous state in
the distant future may well be impossible. (Lorenz
1963, p. 133)
Minuscule differences in initial conditions can
lead to differences far out of proportion in the
system’s subsequent behavior. In this sense,
minor perturbations can essentially be slowly
ampliﬁed to yield major effects. Subtle, cumu-
lative effects, largely undistinguishable from
natural change, perhaps eventually culminate
in profound change (Daughton 2001a;
Daughton and Ternes 1999; Thornton 2000).
This concept has parallels with the idea of “the
tyranny of small decisions” (a term adapted for
ecologic thinking from economist Alfred Kahn
by William Odum) or what Odum refers to as
“small decision effects”—major unforeseen
outcomes resulting from a “multitude of small
pin pricks” (Odum 1982). Moreover, it may
not be possible to detect subtle changes in sys-
tems so complex (e.g., ecosystems) that their
intricately interwoven processes are poorly
understood to begin with. This paradox is fur-
ther complicated by our inability to distinguish
the “normal” functioning of a complex system
from the abnormal. If the basis for comparison
is an already affected system (albeit unrecog-
nized as such), then further detection of any
change can be impaired or obscured.
Proportionality between cause and effect,
although a tenet of single-organism–based tox-
icology, does not necessarily hold for higher
levels of organization such as communities or
ecosystems because of the myriad interactions
and spatial relationships within the system—
some imparting vulnerability to synergistic
effects. When perturbations exceed the
resilience of a system, irreversible change can
occur. Ecologic systems inherit information
(cumulative effects) through time (part of the
4Ts); their complex interlinkages affect one
another synergistically, and their continually
changing complexity makes them vulnerable
to irreversible change. These ideas are formal-
ized in the “community conditioning hypoth-
esis” (Landis 2002, p. 197), where the etiology
of each ecologic structure evolves from a
unique trajectory. This hypothesis holds that
any predictions are rife with uncertainty, but
that most stressors leave lasting signatures, and
stressors can “act from a distance.”
Most recently, the philosophy that all sys-
tems self-organize in perpetual imbalance
(cusps or knife edges of instability, poised at
the edge of chaos), as synthesized by
Buchanan (2001) around nonequilibrium
physics, further consolidates the idea that
small events can trigger disproportionately
large responses that are not predictable—
cause and effect are not linked in certainty,
but rather in surprise. Response is more a
function of the composite history of the sys-
tem than of its snapshot status (the concept of
“historical physics” vs. equilibrium physics,
and as embodied in the 4Ts). Given these
ideas, evidence continues to accumulate that
although it may never be possible to gauge
humanity’s contribution to adverse environ-
mental or human health events or outcomes,
it might behoove us to eliminate as many
extraneous variables (impacts) in ecosystems
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The idea of unexpected change from per-
turbation of ecologic systems is one of the dri-
ving forces behind the precautionary principle.
When applied to assessing risks associated
with chemicals as pollutants, the principle of
precautionary action redistributes the burden
of proof because the science required for truly
and fully assessing risks lags far behind what is
needed. For some comprehensive discussions
on the precautionary principle (also known as
the principle of “reverse onus”), refer to the
links provided at Daughton/U.S. EPA
(2002d). Science, in the face of uncertainty,
must be melded with policy and political
judgment to arrive at a course of further study
or action. Many environmental issues, given
their extreme complexity and the assurance
that a thorough understanding of any isolated
aspect (much less a truly needed, overarching
systems-level, holistic understanding) may
occur only far in the future, will require an
approach based on an unorthodox, dichoto-
mous mixture of subjective (and at times emo-
tional) values wedded to reasoned,
science-based logic; this point relates to the
reasons for the difﬁculties associated with how
science measures “real” hazard versus how
society actually perceives risk (a topic thor-
oughly addressed in a broad body of work;
e.g., Slovic 2001). A recent compilation of
case histories shows how the precautionary
principle did serve (or could have served) in a
variety of situations (Harremoës et al. 2001).
To illustrate that chemicals can have
unforeseen, subtle effects, consider estradiol, an
endogenous hormone excreted to sewage. The
work of Martinovic et al. (2003) went beyond
the common practice of separating a treated
population (male ﬁsh exposed to 25 ppt estra-
diol) from the untreated control. Although no
significant effect was noted in the treated
group in isolation, when the treated group was
placed in competition with the untreated
group, subtle differences became greatly ampli-
fied because of disparities in competitive
advantage. In isolation, competitive advantages
can remain masked, but in the wild they serve
as strong selective pressures. Martinovic et al.
(2003) showed that subtle effects resist
unmasking by using reductionist approaches.
Only systems-level, holistic approaches can
reveal inter-organism interactions, pointing to
the need for more attention to subtle effects
(Daughton and Ternes 1999).
The precautionary principle has a long and
still extremely controversial history. Its adop-
tion by Europe, Canada, and the United States
has proved extraordinarily uneven, inﬂuenced
largely by differences in cultural and political
histories and imperatives. But regardless of the
heated debate surrounding the precautionary
principle, deep-rooted fundamental changes in
corporate philosophies are beginning to emerge
in the way that environmental considerations
are melded with market imperatives—the two
are beginning to merge as it becomes apparent
that many economic advantages (and seemingly
unrelated, and often unforeseen, societal advan-
tages) can be gained by employing environmen-
tal stewardship as a foundation for corporate
philosophy. A proactive, voluntary holistic stew-
ardship program for PPCPs [ﬁrst alluded to by
Daughton (2002a)] would also be preferable to
a reactive, prescriptive regulatory program. By
focusing on developing a mind set toward
holistic, thoughtful environmental responsibil-
ity rather than rote compliance to regulations,
all aspects of society can play integral roles.
This approach is also in keeping with the U.S.
EPA’s new Innovation Strategy (Gibson 2002;
U.S. EPA 2002). Indeed, avoiding the syn-
drome of insidious, cumulative environmental
degradation by way of “small decision effects”
(“multitude of small pin pricks”) may be possi-
ble only in embracing a holistic view of the
world around us (Odum 1982).
The fusion of ecologic and marketplace
imperatives has perhaps emerged most notice-
ably in the relatively recent product manage-
ment philosophy termed “cradle to cradle”
—in contrast to the “cradle-to-grave” approach
that has long been the objective of recycling.
Water Quality: Key to Many
Doors in the 21st Century
The growing, cardinal importance of water for
sustaining societies is becoming more widely
recognized as recently evidenced by its central
role in the Broadway musical Urinetown
(2002). The story is set at a time when “water
is worth its very weight in gold”: 
A depletion of the earth’s water supply has led to a
government enforced ban on private toilets. The
privilege to pee is regulated by a single, malevolent
corporation, which proﬁts by charging admission
for one of mankind’s most basic needs.
A backdrop to the precautionary principle
is the growing imperative for water reuse,
which will prove to be the key, critical driving
force for management of water quality in the
21st century. The NRC, as requested by the
National Science Foundation (NRC 2001),
synthesized the broad expertise from across the
many disciplines embodied in environmental
science to offer its judgment as to the most
signiﬁcant environmental research challenges
of the next generation—based on their
“potential to provide a scientiﬁc breakthrough
of practical importance to humankind if given
major new funding.” Of the eight “grand chal-
lenges” identified in the NRC’s report, two
involve water quality issues, both relevant to
PPCPs: a) hydrologic forecasting (for pre-
dicting changes in freshwater resources as a
result in part of chemical contamination) and
b) reinventing the use of materials. The
impetus driving the second is that
new compounds and other substances are con-
stantly being incorporated into modern technol-
ogy and hence into the environment, with
insufficient thought being given to the implica-
tions of these actions. All of these issues assume
added importance in urban areas, which concen-
trate ﬂows of resources, generation of residues, and
environmental impacts within spatially con-
strained areas. From a policy standpoint, reliable
predictive models of material cycles could be
invaluable in guiding decisions about . . . topics
relating to human-environment interactions. . . .
This grand challenge centrally encompasses ques-
tions about societal-level consumption patterns,
since consumption is the primary force driving
human perturbations of material cycles. (NRC
2001, p. 55)
Likewise, the World Health Organization’s
(WHO) World Water Day Report draws
international attention to the intimate connec-
tion between water and health:
Due to a mix of geographical, environmental and
ﬁnancial factors, as well as to increased pollution
from municipal and industrial waste, the leaching
of fertilizers and pesticides used in agriculture,
only about one-third of the world’s potential fresh
water can be used for human needs. As pollution
increases, the amount of usable water decreases.
(WHO 2001, p. 7)
Links to numerous resources regarding fresh-
water can be found at the World’s Water web-
site (2002). The concept of the “ecological
footprint” (Wackernagel and Rees 1995) also
highlights the central importance of water.
Residents of industrialized countries may need
an average of 10–22 acres per capita to support
an urban lifestyle. One of the major issues fac-
ing water resource managers in the 21st cen-
tury will be to understand the overall impact
of the urban ecologic footprint on water
resources. Although there are numerous conse-
quences of the footprint, a major concern may
be the continued use of urban waterways as
“waste receptacles”—merely for diluting and
transporting downstream the by-products of
urban consumption.
Although this background material empha-
sizes the aquatic environment, it is important
not to lose sight of the other environmental
compartments with which PPCPs can interact.
The most signiﬁcant of these secondary con-
cerns is sewage sludge, to which certain PPCPs
can sorb or partition. Subsequent application
of sewage sludge (“biosolids”) to land (e.g., as a
soil amendment) holds the potential for expo-
sure of terrestrial ecosystems. The NRC revis-
ited the issue of biosolids (NRC 2002b; see
especially chapters 5 and 6) with respect to
reevaluating the approach used by the U.S.
EPA in setting its chemical standards for
the biosolids rule (U.S. EPA Office of
Wastewater Management 2002b). The NRC
recommended that “a research program be
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chemicals likely to be present in biosolids that
are not currently included in routine monitor-
ing programs.” The NRC also recommended
that alternative (i.e., nontraditional) toxic end
points be considered.
Health of Ecology versus
Ecology of Health
The intimate, inseparable connections between
humans and the environment (actually,
humans can be viewed as an integral part of the
environment) have been discussed widely in
many contexts. By applying principles of medi-
cine and public health to the environment,
David Rapport formalized the concepts of
“ecologic health” and “ecosystem medicine”
(Rapport 2002). The “health of ecology” refers
to ecosystem health; the “ecology of health”
refers to human health as determined partly by
the condition of ecology (creation and trans-
mission of antibiotic resistance is one example).
Ecologic stress is reflected by stress in
humans—the two are intimately tied. Adverse
effects in one are eventually reflected in the
other. The Institute of Medicine (IOM), a pri-
vate, nonproﬁt institution that provides health
policy advice under a congressional charter
granted to the National Academy of Sciences,
has called for a revolution and is reengineering
all aspects of the health care system in the
United States. A major objective of the IOM
Committee on Quality of Health Care in
America (formed in June 1998) was to develop
a national strategy to radically improve the
quality of U.S. health care within 10 years. To
date, their recommendations (e.g., IOM,
2001; Kohn et al. 2000) address the many
aspects of patient safety and how the concepts
of quality systems can be applied. Although the
IOM’s goals are far-reaching and urgently
needed, they do not include the concept of
ecology of health. Safety of the patient is pur-
sued out of context of the safety of the ecology.
With a little expansion of the IOM vision, an
integration of human and ecologic health
could be formalized at a national level through
their efforts. High-quality health care and envi-
ronmental protection need not be competing
goals—they are intimately linked.
Connecting Health of Ecology
and Human Health: Health
Promotion and Social
Entrepreneurs
The specific environmental issues and the
example solutions posed in this mini-mono-
graph are not as pertinent to those parts of
the world where PPCPs are little used, such
as economically disadvantaged regions
[except in areas where large-scale drug dis-
posal occurs, e.g., from humanitarian opera-
tions (WHO 1999)] or where illicit drug
manufacturing or use is prevalent (Daughton
2001c). Nonetheless, the basic, universal
concept of a “health state” (rather than an
“absence of illness”)—one of a balanced and
interconnected physical, mental, social, and
spiritual well-being—is equally applicable to
Western cultures and could have a profound
impact on overall drug use (both licit and
illicit). Treatment of physiologic and psycho-
logic symptoms and even the curing of dis-
eases are just one dimension of holistic
health—and in many respects, preventive
and curative approaches are but stop-gap
measures in the absence of a sustainable envi-
ronment. For example, one can argue that
the single most important limitation in the
continual quest to eliminate infectious dis-
eases is not the lack of medication but rather
the failure to address poverty and its atten-
dant liabilities of hygiene and malnutrition.
Many people actively engaged in advancing
the principles of “sustainability” (sometimes
deﬁned as meeting society’s needs in ways not
diminishing the capacity of future generations
to meet theirs) have strongly felt that without
empowering people to take charge of the basic
aspects of their own lives, sustainable improve-
ments in health are not possible. A model
effort (Comprehensive Rural Health Project)
begun in 1970 by the Indian medical doctors
Raj Arole and Mabelle Arole has demonstrated
how a holistic approach builds a foundation
for sustainable living and only then is advance-
ment in improving health possible. Health
cannot be dissociated from all the other aspects
of sustainable living (Arole 2001); the bur-
geoning field of sustainability is captured by
the Initiative on Science and Technology for
Sustainability (ISTS 2002), among others.
Social entrepreneur projects in health promo-
tion (vs. illness/disease prevention), such as
those begun by the Aroles, abandon narrow
technical objectives aimed at preventative and
curative measures in pursuit of wider-ranging
holistic goals that emphasize the interconnect-
edness of social systems.
Cradle-to-Cradle Stewardship
Guided by the interrelationships among the
precautionary principle, the ever-increasing
and key worldwide importance of water, and
the idea of “ecology of health,” the incorpora-
tion of “eco-effectiveness,” “ecologic intelli-
gence,” or cradle-to-cradle design concepts
into life-cycle considerations for product
development and use has gained momentum
in the last decade. The idea of cradle-to-cradle
stewardship has most recently been embraced
by many international corporations. Some of
the more visible and successful proponents of
cradle-to-cradle concepts have been William
McDonough and Michael Braungart (MBDC
2002; McDonough and Braungart 2002).
They have been leaders in implementing the
idea of full life-cycle product design, referring
to this approach as the “next industrial revolu-
tion.” One of the tenets of this philosophy for
a truly sustainable industry is that it benefit
not just the environment but also consumer
and corporation; this is one reason for the
expression sometimes used for these programs:
“waste to wealth.” Numerous similar efforts
have been successfully under way; examples
include those with such monikers as “Zero-
Waste” and “Zero Emissions,” being imple-
mented in Canada by the Recycling Council
of British Columbia (RCBC 2002). Another
effort toward directing organizations toward
sustainability is being led by the international
organization The Natural Step (TNS 2002).
Of the “four system conditions” that The
Natural Step framework is based on, the sec-
ond states that “in a sustainable society, nature
is not subject to systematically increasing con-
centrations of substances produced by soci-
ety.” It is worth noting from an historical
perspective, however, that the idea of sustain-
ability was put forth decades ago, as early as
1966 (Blutstein 2003).
The United Nations Environment Pro-
gramme (UNEP 2002) notes that although
signiﬁcant efforts in reducing environmental
footprints have been made by a few companies
across many industrial sectors, a gap continues
to widen between these few and the vast
majority that continue “doing business as
usual.” Among the five major areas for
advancement toward true sustainability identi-
ﬁed in UNEP (2002), the fourth is the “inte-
gration of social, environmental and economic
issues.” These efforts hint that a sustained
future viability of this product life-cycle phi-
losophy can be expected. A wide range of
strategies that could foster a cradle-to-cradle
approach for stewardship of PPCPs by the
pharmaceutical/medical care industries could
be adopted. Some could be implemented
quickly (requiring only a collective will to
implement them); others would require sus-
tained research and development efforts
(which in some cases are already under way,
albeit for reasons unrelated to environmental
benefits), and some would require major
attention by the numerous agencies involved
with a patchwork of laws and regulation of
drug recycling and disposal. Several examples
are outlined in various sections of this mini-
monograph.
Viable Options for Minimizing
the Introduction of PPCPs to
the Environment
Numerous actions could be implemented in
the near term for reducing what risks might
exist from introducing PPCPs to the envir-
onment. In the longer term, a number of
research avenues could be pursued regarding
drug design, packaging, and delivery—all of
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as consumer) paybacks. Indeed, some of these
are already being pursued. Many would yield
direct benefits to human health for reasons
unrelated to any environmental imperative,
including reducing inappropriate drug use
and lowering therapeutic dosages [thereby
lessening adverse drug reactions (ADRs) and
reducing consumer costs].
Many pharmaceutical producers and orga-
nizations have “product stewardship” as an
integral part of their business. These programs,
however, although sometimes acknowledging
the issues associated with consumer use of
PPCPs, tend to focus on aspects of the manu-
facturing process (vs. distribution and use) as
well as on hospital waste (Daughton/U.S. EPA
2002e). A potential mechanism for effecting
change in the health care industry (starting
with hospitals) is via an existing program estab-
lished under a program agreed to in 1998 by
the American Hospital Association and the
U.S. EPA and administered by the Hospitals
for a Healthy Environment (H2E 2002). This
program’s overall goal is to reduce the impact
of health care facilities on the environment.
Although the program initially focused on
eliminating mercury and reducing total waste
volume, a future area to consider is develop-
ment of model chemical waste minimization
plans such as that developed for mercury by
H2E (2002).
Some of the ideas presented below may
prove controversial. I highlight them solely to
generate an active dialog or debate across the
many disciplines that must become involved to
successfully address this topic. Many of these
disciplines have never before had reason to
interact or collaborate with each other. With
the increasing visibility of PPCPs as pollutants,
I hope these disparate professional communities
will ﬁnd compelling reasons to cross-communi-
cate and, in doing so, expand their knowledge
and effectiveness in their own ﬁelds.
Avenues for Progress toward a
“Green Pharmacy”
The last decade has seen tremendous progress
in advancing the practice of “green chemistry”
(e.g., minimizing the use of ecologically haz-
ardous reagents and designing alternate synthe-
sis pathways, some of which are based on
aqueous chemistry) (U.S. EPA Office of
Pollution Prevention and Toxics 2002). In
fact, the pharmaceutical industry has a strong
history of applying environmentally responsi-
ble chemistry (which also turns out to be eco-
nomically advantageous) to drug synthesis and
manufacturing. The same principles could be
logically extended and applied to drug design,
delivery, package design, dispensing, and dis-
posal so that their beneﬁts could accrue to the
end user and not just the manufacturer. Some
of these ideas for minimizing the release of
PPCPs to the environment have already been
put forth (Daughton and Ternes 1999) but are
reiterated and expanded on here because all
these ideas have never been brought together in
one document. Unfortunately, despite the
many avenues of advancement that could be—
and sometimes are already being—made
toward a green health care system, the transfer
of new knowledge and technology to clinical
practice is notoriously slow; as one example,
new knowledge gained from clinical trials takes
an average of 17 years to become incorporated
into routine practice (IOM 2001).
Drug Design
New drug design (chemical structure and
properties) and formulation (combination of
the active, therapeutic ingredient with the
inert, nonactive ingredients known as excipi-
ents) should factor in new considerations for
“environmental friendliness” or “environmen-
tal proclivity.” Such “green” PPCPs would
maintain or improve therapeutic or cosmetic
efﬁcacy while also maximizing their susceptibil-
ity to biodegradation, photolysis, or other
physicochemical alterations to yield innocuous
end products. Design of more labile drugs
(e.g., those that would ordinarily be degraded
by or poorly transported across the gut) would
further reduce excretion. Current drugs that do
undergo initial structural alterations (e.g., via
phase I or phase II metabolism) often yield
broad arrays of metabolites, some of which are
the actual active drug form and some of which
are environmentally persistent; compared with
what little is known regarding effects to non-
target species by parent drugs, even less is
known about metabolites. Drugs could be
designed with better physiologic sorption char-
acteristics (to lessen direct excretion of the par-
ent compound). Using smaller doses by
enhancing the delivery exclusively to the target
site or receptor is an objective being pursued
on many fronts, including better drug design
to accommodate existing membrane trans-
porters (e.g., XenoPort 2002) and “creating”
in situ synthetic transporters (Alper 2002).
Sometimes the formulation of a drug can
impede its sorption, especially for those with ill
health or impaired gastrointestinal function.
Rapid-dissolve tablets are one example of an
improvement over formulations that can
impede or prevent dissolution; for example, the
common excipient stearic acid often impedes
dissolution (Daughton 2001a). New formula-
tions are particularly needed for insoluble
drugs [about 30% of U.S. Pharmacopeial
Convention, Inc. (USP) drugs and 50% of
prospective drugs are poorly water soluble];
current examples include liposomal delivery,
polymer-drug conjugate prodrugs (with release
at the target site), and special formulating
approaches, such as “insoluble drug delivery”
(SkyePharma 2003). Other examples include
novel targeting approaches such as patient re-
infusion of autologous erythrocytes that have
been altered to encapsulate drugs and permit a
steady, low-drug concentration to be attained
for a period of weeks and that can selectively
target certain sites such as macrophages
(Magnani et al. 2002).
The future of omics. The rapidly advanc-
ing “omics” revolution [e.g., genomics, pro-
teomics, glycomics, metabolomics; Cambridge
Healthtech Institute (CHI) 2002] will proba-
bly lead to the development of countless new
classes of drugs (some with mechanisms of
action never before encountered by any organ-
ism, and therefore posing the attendant ques-
tions as to the possibilities for previously
unconsidered effects on nontarget organisms).
But at the same time, identiﬁcation of genetic
idiosyncrasies will allow the selective targeting
of speciﬁc subpopulations of patients for treat-
ment with these same new drugs—thereby
allowing for their reduced use across the larger
population. “Pharmacogenomics” holds great
promise to a) greatly increase the numbers of
low-use drugs (those specifically tailored to
narrowly defined patient populations, effec-
tively vastly increasing the number of thera-
peutic niches), and b) increase the numbers of
high-use (blockbuster) drugs (by addressing
therapeutic targets of minimal genetic variabil-
ity across the population to yield drugs of
extremely broad tolerability). By increasing the
efﬁciency of drug discovery (minimizing fail-
ures), the reduced costs will in turn catalyze
yet more new-drug discovery. “Genomics” is
also recognized by the U.S. EPA as providing
new opportunities for risk assessment and pre-
dictive toxicology and will continue to gain
new applications (U.S. EPA Science Policy
Council 2002).
Dirty drugs to designer drugs. With better-
designed drugs (vs. those with a broad spectrum
of molecular actions—“dirty” or “promiscuous”
drugs), by increasing the specificity of drug
action at the target receptor, not only could
adverse reactions be minimized, but with
extremely narrow MOAs it would also prove
easier to predict the potential for effects on
nontarget species. Another example (regarding
drug discovery/design) is the development of
drugs with higher potencies (and therefore
lower doses) as a result of greater systemic avail-
ability. Drug potency is partially a function of
absorption efﬁciency (lower doses necessitated
by higher absorption efﬁciency). Recently, as
reported by Veber et al. (2002), reduced molec-
ular ﬂexibility (as measured by the number of
rotatable bonds) coupled with lower polar sur-
face area (or total hydrogen bond count) was
shown to reflect good oral bioavailability—
independent of low molecular weight (MW) or
lipophilicity. Absorption had been thought to
be a strict function of MW (e.g., MW > 500
daltons led to poor absorption; low MW was
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in rats, however, Veber et al. (2002) showed
that it is not necessarily MW but rather the
rigidity of the molecule (which is partly an indi-
rect function of MW) that is a prime determi-
nant. This points to the possibility that
higher-MW drugs for humans are possible as
long as the number of rotatable bonds is mini-
mized. For rats, the more rigid molecules (those
with 10 or fewer rotatable bonds and lower
polar surface area) show the better oral absorp-
tion; lowest absorption occurs with those hav-
ing more than 10 (“ﬂexible” compounds). The
rule of ﬁve (Lipinski et al. 1997) as a predictor
of oral bioavailability posits that either the
number 5 or a multiple of 5 was involved in the
predictive parameters (but there were only four
rules in the “rule of ﬁve”): “In the discovery set-
ting ‘the rule of 5’ predicts that poor absorption
or permeation is more likely when there are
more than 5 H-bond donors, 10 H-bond
acceptors, the molecular weight . . . is greater
than 500 and the calculated Log P . . . is greater
than 5.” The number of rotatable bonds (Veber
et al. 2002) would add the ﬁfth rule.
Chirality’s role. Design that lessens thera-
peutic doses without increasing overall
potency is already occurring with the emphasis
on enantiomerically pure drugs (homochiral
drugs), which can have therapeutic advantages
over their conventional racemic mixtures. One
of the first commercial examples was (R)-
albuterol or levalbuterol (Xopenex; Sepracor,
Inc., Marlborough, MA), the homochiral ver-
sion of racemic albuterol; broncodilation
could be achieved with levalbuterol at one-
fourth the dose of racemic albuterol (and with
fewer side effects) (Handley et al. 2000). A
more recent example is esomeprazole
(Nexium; AstraZeneca, Södertälje, Sweden),
the homochiral form of omeprazole (Prilosec;
AstraZeneca). This approach not only cuts the
overall dose by at least one-half (sometimes
more, depending on the number of isomers)
and totally eliminates exposure to the other
(nontherapeutic) isomer(s), which frequently
has completely different mechanisms of
action, but can also yield benefits to the
patient by removal of nontherapeutic isomers
that were also responsible for unwanted side
effects. The commercial-scale production of
homochiral drugs, however, is fraught with
scale-up difficulties; advances in economic
racemic separation efﬁciencies will prove use-
ful (e.g., see Lee et al. 2002). The develop-
ment of enantiomerically pure drugs to reduce
environmental loadings has a parallel with pes-
ticides. Optically pure pesticides have been
approved by the U.S. EPA (e.g., S-metolachlor)
under the U.S. EPA’s Reduced Risk Pesticide
initiative (under the Food Quality Protection
Act; U.S. EPA Office of Pesticide Programs
1996). For metolachlor, this might lessen its
overall use by 35%.
Emulating nature. Another design strategy
would be “smart” drugs that better emulate
the nonanthropocentric, native chemistries of
natural products. As examples, consider a) the
newer classes of antimicrobial peptides mod-
eled after the endogenous antimicrobials (e.g.,
defensins, piscidins, and cathelicidins; Toma
2001), b) bacteriophages (viruses that infect
only bacteria; e.g., see Intralytix 2002), and
c) the enzymes used by phages to destroy their
bacterial hosts (e.g., highly species-specific
lysins). One new approach uses synthetic
cyclic peptides (some with the non-native
optical isomers) to disrupt cell wall/membrane
function or physical integrity (Fernandez-
Lopez et al. 2002). Although naturally pro-
duced antimicrobials and analogs may not be
sufﬁcient on their own, their use could serve
to potentiate the action of existing synthetic
antibiotics and thereby reduce overall use.
These natural products could also reduce over-
all antibiotic use by prophylaxis—in prevent-
ing the onset of infection. Another example is
the synthetic musk fragrances. The two classes
that have been used extensively are the nitro
musks and the polycyclic musks. Certain
members of these classes (or their metabolites)
are known to persist and bioaccumulate
(Daughton 2001a; Daughton and Ternes
1999). A third class that is not used as exten-
sively because of its cost comprises the macro-
cyclic musks (15–18 carbon cycles closed as
either a carbonyl or lactone), which better
emulate natural musks and are purportedly
more biodegradable.
Avenues to resurrection. “Resurrection” of
“retired” drugs that are no longer efﬁcacious
(e.g., because of development of pervasive
pathogen or tumor resistance) could allow for
the continued use of older-generation drugs
that could be more environmentally friendly.
Resurrection could be accomplished by devel-
oping potentiators that are not inherently
toxic but that overcome, for example, the
defensive strategies used by resistant target
organisms or tissues. An example is the devel-
opment of multidrug efﬂux pump inhibitors
(EPIs) (Daughton and Ternes 1999). One (of
many) example class of existing EPIs is that
containing certain selective serotonin reup-
take inhibitor antidepressants (Munoz-Bellido
et al. 2000), which synergize the activity of
some antibiotics. But strategies designed to
counteract general defensive strategies (such
as efﬂux pumps) must be assessed carefully in
light of their potential for compromising the
health of nontarget species, many of which
(especially in the aquatic realm) employ efﬂux
pumps as a first line of defense against toxi-
cants (Daughton 2001a; Daughton and
Ternes 1999; Epel and Smital 2001).
Alternative medicines missing from the
radar. The WHO developed a strategy for
addressing issues of policy, safety, efficacy,
quality, access, knowledge preservation/
protection, and rational use of “traditional,
complementary, and alternative medicine”
(TM/CAM) (WHO 2002b). That the WHO
put forth this ﬁrst global strategy clearly sig-
nals that TM/CAM has gained substantial
stature. The popularity of TM/CAM in less
developed countries is widely appreciated; its
growth in more developed countries over the
last two decades is reﬂected by the prolifera-
tion of websites devoted to it. Because many
active ingredients in natural medicines are
highly bioactive, the same concerns regarding
environmental fate and ecologic effects apply
(Daughton and Ternes 1999) and should
therefore be subject to similar scrutiny. But
the WHO strategy does not address any issues
concerning disposal or pollution prevention.
In many countries, environmental risk
assessments of varying degrees are required at
least for new drug entities meeting certain cri-
teria. Although the existing regulations for
these assessments (e.g., see discussions in
Velagaleti and Gill 2001; Velagaleti et al.
2002) as well as those under consideration
(e.g., CSTEE 2001; Health Canada 2002)
have the potential to evolve over time in
response to new science regarding environmen-
tal impacts, similar assessments for dietary sup-
plements, “alternative” medicines, and other
personal care products do not exist. Given that
the biologic activity of many of these chemicals
can rival that of drugs (e.g., Daughton and
Ternes 1999), it would be prudent to also sub-
mit these diverse chemical classes to environ-
mental risk assessments; currently, they are
completely free of any oversight regarding eco-
logic hazard, and many escape assessment of
human health risk. Indeed, the fact that nutri-
tional supplements can elicit profound biologic
effects is becoming codiﬁed in medical refer-
ences (e.g., PDR 2002a, 2002b) where com-
monly recognized cross-reactions with
conventional drugs have already been noted—
for example, with Saint John’s wort (a potent
inhibitor of certain drug-activating enzymes).
Drug Delivery
Eco-friendly strategies to implement in the
area of drug delivery include those relevant to
prescribing, dispensing, patient compliance,
and medication delivery mechanisms. Some
advanced ideas regarding delivery mechanisms
can be gained from Mort (2000).
Prescribing. Both physicians and the public
could be made more aware and better informed
as to the medical and environmental conse-
quences of overprescribing medications. Better
ways need to be found to engage the medical
community and the public in this issue.
Guidelines could be developed and promul-
gated for minimizing inappropriate drug use
(misuse, overuse, and abuse). Regarding the
linkage between human and ecologic health,
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for the issue of antibiotics (see links in
Daughton/U.S. EPA 2002f), where physician
knowledge and patient expectations are com-
monly at odds and antibiotics are sometimes
prescribed (because of patient expectations) in
situations where they are not justified.
Imprudent use also involves failure to identify
putative pathogens and to perform susceptibil-
ity testing before selecting the most effective
antibiotic. The literature continues to docu-
ment circumstances where antibiotics have long
been used but should not have been; a recent
example is their inappropriate use for bronchitis
(Evans et al. 2002). Others who should attempt
to minimize the misuse of antibiotics are veteri-
narians, aquaculturists, and agriculturists to
lessen the incidence of resistance development
in native bacteria and human pathogens (e.g.,
Lipsitch et al. 2002; Smith et al. 2002). An
example of a creative approach to minimizing
the use of antibiotics for the common cold is
presented by Arroll et al. (2002). By giving
patients antibiotic prescriptions that could be
ﬁlled only 3 days thence, overall use was 48%
as opposed to 89% for those having immediate
access to antibiotics for “treating” common
cold symptoms—nearly halving their use and
avoiding exposing the patient to unnecessary
medication.
Lower versus established dosing. Numerous
studies show that the therapeutically effective
dose for many drugs can be signiﬁcantly lower
than that initially recommended by the manu-
facturer. There are many reasons for this
(including some stemming from regulatory
requirements during clinical trials), which are
summarized by Crutchﬁeld (2001). Sometimes
the effective dose for a drug can be many orders
of magnitude lower than previously realized,
largely a result of incomplete knowledge
of MOAs. An excellent example is the conven-
tional therapeutic dosage of morphine to
achieve analgesia—typically about 1–10 mg/kg.
With simultaneous administration of an opioid
receptor antagonist (i.e., naltrexone) at the
ultra-low dosage of 0.1 ng/kg, the same con-
ventional level of analgesia can be achieved with
morphine at 1 µg/kg—6 orders of magnitude
lower (a dosage that can be sustained without
risk of addiction); similar effects can be
achieved with 0.1 µg/kg morphine coupled
with 1 pg/kg naltrexone (Crain and Shen 2001;
Pain Therapeutics 2002). This is an excellent
example of research that could markedly reduce
patient risk by reducing side effects or ADRs
and even addiction while minimizing the
potential for environmental effects. Most hospi-
tal ADR-related deaths are related to dose, and
ADRs may be a leading cause of hospital death
in the United States (Lazarou et al. 1998).
Indeed, deaths from medication errors occur-
ring both in and out of hospitals exceed 7,000
annually in the United States—exceeding those
from workplace injuries (Kohn et al. 2000).
Moreover, Kohn et al. (2000) maintain that
extrapolation of certain statewide studies to the
United States as a whole shows that annual
excess costs of preventable hospital ADRs are
about $2 billion (and hospital patients repre-
sent only a small portion of the at-risk general
population).
Precision formulation/dosing. Current
technology for formulating drug dosages
is incapable of high accuracy or precision,
especially that needed for ultra-low doses.
Nonhomogeneous formulation or inconsistent
delivery can lead to undesirable repeated dos-
ing and improper dosing (e.g., Alliance
Pharmaceutical 2002). New technologies such
as “three-dimensional printing” can formulate
accurate, precise, and minuscule amounts of
drugs into one delivery device to achieve better
temporal and spatial control of drug release via
any combination of sustained, controlled, tar-
geted, or cyclical methods. With the ability to
control the drug release “proﬁle” (tailored to a
variety of factors, including time after inges-
tion or circadian rhythm), more effective and
lower doses can be achieved (MIT 3DPTM
Laboratory 2002; MIT News 1997).
Individualization of therapy. Drug man-
ufacturers could provide the medical com-
munity with more easily implementable
information (and requisite unit doses) to tai-
lor drug dosages for the individual (especially
for long-term maintenance drugs) on the
basis of the sometimes complex interplay
among body weight, age, sex, health status,
nutritional status, timing/circadian rhythm,
subtle genetic distinctions (e.g., accommoda-
tion for single-nucleotide receptor polymor-
phisms using new toxicogenomics tools), and
known individual drug sensitivities. Several
companies are currently involved in ap-
proaches based on genetic variabilities to per-
sonalize drug therapy (e.g., Genaissance
Pharmaceuticals 2002; Orchid Biosciences
2002). Currently, customized doses and for-
mulations are often obtainable only from pri-
vate pharmacy “compounders”—not drug
manufacturers—and are not subject to FDA
rules for quality. Such individualization of
therapy (also known as “calibrated dosing”)
can minimize the requisite therapeutic dose
(which is frequently higher than need be)
(Phillips et al. 2001). Available tests for drug
metabolizing enzymes (e.g., the cytochrome
P450 superfamily of monooxygenase iso-
forms) can distinguish fast, normal, and slow
variants. These enzyme systems play major
roles in the speed with which certain drugs
are metabolized (whether leading to detoxiﬁ-
cation and excretion or to activation) and
therefore determine the proper dosage.
Advances in detection of other physiologic
and metabolic characteristics of a patient can
also allow for the speciﬁc targeting of a drug
for its intended site (to reduce unnecessary
systemic exposure).
Individualized therapy can also help to
address the growing trend of the healthy pop-
ulation that medicates on a long-term basis
using a wide array of drugs as preventive mea-
sures (attempting to prevent the onset of vari-
ous health problems). Outcomes from the use
of medications by healthy people for dura-
tions spanning decades prompt numerous
questions regarding patient safety and the
consequent issue of imprudent introduction
of drugs to the environment. But long-term
studies (those lasting for decades) are rarely
performed because patents do not offer pro-
tection sufﬁciently long to justify the cost. It
is possible that in place of new studies, the
vast collection of individual, small reports
already in the published literature could be
distilled into useful knowledge. Much of what
exists in the published literature is never
“mined” and applied (Daughton 2001b,
2002b). An example of one step in the direc-
tion of mining the existing literature and using
it to predict adverse drug outcomes is an
approach called “evidence-based care,” where
recommendations are collectively made by
physician experts who continually scan the
broad medical literature and synthesize recom-
mendations (evidence-based rules) regarding
drug use across patients comprising a wide
spectrum of health status (e.g., ActiveHealth
Management 2002).
Developing alternative delivery mecha-
nisms. Dosages could be reduced with better
targeted delivery routes (e.g., expanding the
utility of pulmonary and transdermal/mucosal
delivery), mechanisms of release (e.g., rapid-
dissolving formulations, controlled release),
and mechanisms for delivery of drugs to the
target (e.g., antibody-linked drugs; in situ
implants) (e.g., Mort 2000). Advancement in
eluding the blood–brain barrier would vastly
expand the universe of available central ner-
vous system drugs, which are currently
restricted to a small galaxy of drugs smaller
than 500 daltons; selective disruption of the
blood–brain barrier, either via momentary
enlargement of the endothelial cell junctions
or by use of native membrane transporters, is
one example (Miller 2002). Although
advancement in drug delivery has received
concerted attention over the years (e.g., see
ACS 2002; CRS 2002), expanded efforts in
this area (e.g., by leveraging with nanochem-
istry) could yield significant rewards, espe-
cially with respect to resurrection of “retired”
or underused drugs.
A potential future route/mechanism is the
use of “click chemistry” for the self-assembly
of drugs in situ, where the nonbioactive pre-
cursor reactants required to synthesize a drug
are self-assembled directly at the receptor tar-
get (the “templating” site; e.g., Borman 2002).
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synthesis is sometimes called “bioinspiration.”
This approach for drug delivery perhaps holds
the ultimate potential for minimizing dosage.
In situ click chemistry (a new rendition of in
situ, site-catalyzed synthesis) uses the speciﬁc
conformational locations within biochemical
receptor molecules as templates for guiding
the formation of a chemical product with high
afﬁnity for the site. Candidate drugs generated
in this manner also would have a higher prob-
ability for speciﬁcity—avoiding the propensity
for promiscuity (“dirty” drugs), a problem that
has plagued drug discovery for years—and
thereby further reducing required doses
(McGovern et al. 2002). Interactions with
receptors that do not provide intended thera-
peutic effects are sometimes called “sites of
loss” and are often the cause of ADRs. The
work done with current in situ click chemistry
shows the ease with which small molecules
with ligand interactions at the femtomolar
level could be achieved. An acetylcholines-
terase inhibitor formed via click chemistry
proved to be the most potent noncovalent
inhibitor ever found for this enzyme. It may
eventually prove possible to set the conditions
for the self-assembly of reactants at the desired
site of biochemical action within the living
organism, to prevent reaction with nontarget
sites. Such an approach would effectively
achieve the lowest possible dose for a drug
(forming the ultimate “smart” drug), thereby
minimizing or even eliminating the possibility
for excretion to the environment.
Patient compliance and education. Patients
frequently fail to ﬁnish their courses of medica-
tion—for a wide variety of reasons (Daughton
2003). This problem not only increases health
care costs and can jeopardize patient health but
also leads to unnecessary accumulation of
unused drugs, which then require disposal [this
is a major problem at long-term care facilities,
discussed in Daughton (2003)]. Further educa-
tion of patients might reduce patient noncom-
pliance. Additional patient education regarding
appropriate drug use (as deﬁned in USP 2001)
and drug abuse (consumption of more fre-
quent or higher doses than prescribed, or use
of illicit drugs) could reduce unnecessary excre-
tion or disposal. A recent example of proactive
guidance on minimizing commonly overpre-
scribed drugs is the U.S. Centers for Disease
Control (CDC) campaign called Promoting
Appropriate Antibiotic Use in the Community
(CDC 2002). By showing the linkages
between human and ecologic health beneﬁts,
perhaps more progress can be made in mini-
mizing overuse/misuse of legal drugs (e.g.,
antibiotics) and illicit drugs; also of relevance is
the linkages between illicit drug use and terror-
ism [Daughton/U.S. EPA 2001; Office of
National Drug Control Policy (ONDCP)
2002].
Education of health care practitioners.
Hand-in-hand with education of the public is
education of those working in the health care
industry (not just pharmacists, but all health
professionals and technicians, federal and
state policy makers and regulators, organiza-
tion managers, and governing boards). A
good way to teach the importance of dose
minimization and proper disposal would be
through formal, continuing education
courses, where the interface between medicine
and environmental science and the synergies
accrued from cradle-to-cradle stewardship of
medications could be taught. Along these
lines, Smith (1999) proposed that the USP
include hazardous waste criteria in its mono-
graphs; this recommendation could be
extended to include disposal guidance for all
nonhazardous, noncontrolled drugs as well.
Marketing
Guidance on packaging for disposal.
Consumer-oriented packaging for OTC and
prescribed drugs in the United States lacks
guidance for disposition of unused medication
contents. Standardized nationwide guidance
regarding recommended routes for responsible
disposal (which could be custom tailored
depending on the ingredients) could be easily
added to package labeling/inserts. The use of
consumer guidance on labeling for protecting
the environment has long been common with
other consumer products throughout the
world, especially for pesticides and industrial
chemicals. Standards that cover the entire
packaging system are developed and promul-
gated by the USP. The many complex aspects
of packaging are summarized in Okeke (2002).
In the United States, consumer warning and
use information regarding drugs is conveyed
not just on afﬁxed labels but also on attendant
documents such as prescription “leaﬂets,” the
minimum information content for which is set
by the U.S. FDA. For prescription drugs, these
leaflets are supposed to contain (at a mini-
mum) the FDA-approved prescribing informa-
tion (also called a package insert). Various
other sources of consumer (as well as physi-
cian) information on drugs can be found in a)
the Physicians’ Desk Reference (PDR 2002a),
which contains the required prescribing infor-
mation for most but not all drugs (the printed
version is updated three times per year, the
online version monthly, and the personal digi-
tal assistant version daily); b) any of the various
compendia such as Drug Facts and Comparisons
(Facts and Comparisons 2002), which is
updated with labeling changes monthly; and c)
MedWatch (U.S. FDA 2002b). The U.S.
FDA’s new labeling requirements for OTC
drugs are one example of labeling status in U.S.
drugs (U.S. FDA 2002c). These are all exam-
ples of information resources that could convey
information regarding possible environmental
ramiﬁcations and disposal advice—comporting
with the ideas of ecology of health and health
of ecology.
Steps in this direction are already being
taken. For example, EMEA (2001) has already
taken this step in recommending labeling pro-
visions. A consumer survey sponsored by
Health Canada showed that a large majority of
respondents read drug labels, but fewer than
50% read labels for personal care products
(COMPAS 2002). Although most consumers
claim to read labels for ingredients, when
unprompted by the interviewer, few (only 8%)
claim to read them for information regarding
“environmental-friendliness/impact.” But
when prompted, 57% said they do read labels
for guidance regarding disposal (in Canada).
Guidance on packaging to prevent unneces-
sary dosing (aggregate and cumulative).
Inadvertent ingestion of multiple drugs sharing
the same MOA (joint action from cumulative
exposure; Figure 2) or ingestion of the same
drug from different sources (aggregate expo-
sure) can occur when consumers use multiple
medications without fully understanding the
formulated contents. This multiple-exposure
pathway scenario is especially problematic
when patients are prescribed medications by
multiple physicians; for patients with multiple
health care providers, poor communication can
also lead to represcribing of medication that
has already been shown for the patient to be
nonefficacious. Besides prominently listing
contents on labeling, it would also be useful to
consumers to list the actual therapeutic end
points. For example, analgesics are often for-
mulated into multiple classes of medications,
including those such as pain killers, antihista-
mines, and cold/flu preparations, and con-
sumers sometimes take all of these together,
getting doses higher than needed. By better
alerting the consumer to those drugs intended
for different therapeutic end points but which
share the same active ingredient or that share
ingredients with the same mechanism or mode
of action, the use of certain drugs could be less-
ened and the likelihood of consuming doses
higher than necessary could be reduced. This is
analogous to the current practice of alerting
consumers to adverse interactions between
drugs having different mechanisms of action.
The significance of this type of combined
(aggregate and cumulative) exposure is cap-
tured by the concept of the Risk Cup (Figure
2), a term that establishes by analogy of water
in a cup the sum total of stressor exposure
evoking a particular effect or end point (and
therefore the remaining exposure that could be
tolerated before the cup becomes full). One
possible mechanism for reducing this problem
is presented in Daughton (2003).
More informative and less confusing drug
names. The IOM recommends that better
efforts be made to eliminate drug names that
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similar, as well as confusing labels and packaging
that foster mistakes by consumers, health care
providers, and dispensers (Kohn et al. 2000).
Although these problems can jeopardize patient
safety, they also lead to unnecessary (and inap-
propriate) use of drugs and their eventual dis-
charge to the environment, as well as to the
purchase of medications that might not have
been made by a better-informed consumer.
Reducing package sizes. Consideration
could be given to providing a broader selec-
tion of package sizes of PPCPs. Some PPCPs
are perhaps more likely to be discarded
because they are prescribed or purchased in
quantities too great to be used before expira-
tion or because they tend to expire more
rapidly. A common example is aspirin and cer-
tain nonsteroidal anti-inflammatory drugs,
which are available in such large package sizes
that the contents may frequently go unused
before reaching expiration. Alternatively, bulk-
size packaging could incorporate individually
factory-sealed subpackages whose expiration
dates are maintained even when the seal to the
main container is broken. Consumer educa-
tion might also be useful here—to encourage
purchase of only needed amounts of PPCPs
(e.g., package sizes conducive to avoiding expi-
ration). Consideration should therefore be
given to not penalizing consumers monetarily
for purchasing small-quantity package sizes (or
perhaps offering “introductory size” samples).
Improved packaging. Package materials
and sealing mechanics could possibly be
improved to enhance both factory-sealed and
dispensed shelf lives (e.g., more effective
exclusion of humidity and heat, which are
major factors limiting the storage life of drugs
in bathrooms). Ideally, packaging could inte-
grate inexpensive sensors (customized for each
drug) that are capable of detecting breakdown
products indicative of degraded drug perfor-
mance or formation of products presenting
adverse risk.
Advertising. Since the 1800s, PPCP direct-
to-consumer (DTC) advertising in the United
States has played an increasingly signiﬁcant role
in relaying information to the public regarding
the many aspects of improved health, ﬁtness,
and appearance, as well as the prevention of dis-
ease (Duke University 2002). Only more
recently have advertisers been required to high-
light the caveats associated with their products
(e.g., side effects or contraindications). DTC
advertising purportedly empowers consumers,
leading them to better-informed decisions and
improved quality of care (e.g., National Health
Council 2002; PhRMA 2003). But critics of
DTC advertising (which is one of the most
heated topics in the medical care industries of
many countries) maintain that it can interfere
with the physician–patient relationship (e.g.,
leading to “doctor shopping”) and lead to the
pressuring of physicians to prescribe expensive
and sometimes unnecessary medications
for demanding, poorly informed patients
(Rosenthal et al. 2002); some countries have
banned or minimized DTC advertising (e.g.,
Galbally 2000; Meek 2001). Regardless of the
fate of DTC, a logical next step for advertise-
ments could be to include information for the
public regarding the proper disposition of
unused products and the imperative for envi-
ronmental stewardship.
Advertising can also educate consumers in
decisions to use a new drug. A criticism of the
reporting of controlled drug trials involves the
signiﬁcance of treatment outcomes. Two mea-
sures of significance are often used—not in
conjunction with each other, but separately—
without explaining their relative meanings.
The measure of a new drug’s effectiveness is
usually expressed in comparison with an
accepted standard treatment. If the new drug is
more effective, its comparative effect can be
expressed in terms of either absolute risk reduc-
tion (ARR; or its reciprocal, number needed to
treat) or relative risk reduction (RRR). RRR
data often seem to have a much higher per-
centage of effectiveness than ARR data (Nuovo
et al. 2002). Sometimes, when the RRR might
convey to the consumer a major advance in
treatment, in reality it might be minuscule in
terms of absolute improvement (ARR) over
current therapy.
Drug Dispensing
Internet dispensing. The availability of licit and
also illicit drugs via the Internet (via both legal
and illegal “Internet pharmacies”) and black
markets continues to escalate and expand,
undoubtedly leading to overdispensing and
dispensing without a prescription (U.S. FDA
2002a). The added inﬂux of drugs to the envi-
ronment via illegal sales that were never antici-
pated by FDA during new drug approval is
undoubtedly contributing to the overall envi-
ronmental exposure burden. That many of
these sales come from overseas may have rami-
fications for performing environmental risk
assessments for drugs. Uncontrolled drug dis-
tribution channels also have profound ramiﬁ-
cations for consumers in terms of safety and
expense (e.g., “fake,” counterfeit, or unstated
dangerous ingredients) and also could be a
major factor in both the accumulation of
unused drugs and the excretion of drugs that
ordinarily might never have been ingested.
Both the public and the pharmacy communi-
ties might beneﬁt by more deﬁnitive education
on these issues and understanding the possible
environmental consequences. This awareness
could minimize unneeded drug use and
attendant disposal. One way for consumers to
verify the quality of Internet pharmacies is to
check for the presence of the Veriﬁed Internet
Pharmacy Practice Sites (VIPPS) hyperlink
seal. The National Association of Boards of
Pharmacy developed this certiﬁcation program
for Internet pharmacies in 1999; few Internet
pharmacies are VIPPS certiﬁed (NABP 2002).
Detection of counterfeiting. Regarding the
gray- and black-market distribution of drugs,
industry experts suggest that some 25% of the
unauthorized distribution of pharmaceutical
drugs takes place online (Cyveillance 2001).
Although development of deterrents for black-
market distribution of drugs (and counterfeits)
has always made economic sense for manufac-
turers (e.g., Green and Murray 2001), it would
also clearly reduce the quantities of drugs avail-
able for eventual introduction to the environ-
ment (by both direct disposal and excretion).
Advancements are needed in detecting molecu-
lar counterfeiting; an example is Biocode’s
anticounterfeiting efforts (Biocode 2002).
Nationwide database of drug sales. A
publically accessible, central database that
compiles and tracks geographic OTC and pre-
scribed drug sales as well as drug use (not to be
misconstrued as a patient-level database) would
be extremely useful for predicting the actual
quantities of drugs that could be entering the
environment (by using pharmacokinetic mod-
els based on ADME/Tox—adsorption, distrib-
ution, metabolism, excretion, and toxicity)
(Daughton/U.S. EPA 2002g). Such a database
would have great added utility for environ-
mental scientists if it were integrated on a
geographic information system platform to
enhance the geographic utility of the data;
first steps in this direction have been made
and reported by Schowanek and Webb
(2002). Data from the Prescription Drug Atlas
(Express Scripts 2001) show that for some
drugs, regional preferences in use can vary by
severalfold. First steps in this direction
include proprietary databases such as the
extensive ones developed by Quintiles (2002).
The Quintiles Rx Market Monitor (Quintiles
2000) uses near–real-time patient claims trans-
actions to mine accurate drug use statistics at
the geographic level.
Nationwide database of drug returns. An
active “returns” industry (Daughton 2003)
expanded to the consumer level would have
obvious positive ramiﬁcations for the environ-
ment. Less appreciated, however, is that a
cohesive nationwide policy encouraging the
return of unused drugs to pharmacies or
directly to reverse distributors (see links at
Daughton/U.S. EPA 2002h) yields a number
of consumer health and economic beneﬁts by
mining the data generated by a nationwide,
integrated “returns” network. In the United
States, however, a morass of sometimes con-
ﬂicting and competing oversight and liability
concerns from numerous state and federal
agencies stymies the creation of a cohesive
approach to returning/recycling medication
from the end user (Daughton 2003).
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ramifications for calculating EECs/PECs. As
mentioned above, environmental assessments
for approval of new drug applications are
required by the U.S. FDA only when the con-
centration of a drug predicted to enter the
aquatic environment (EEC) is 1 ppb or greater.
But calculation of the EEC (or PEC) assumes a
uniform use of a drug across the United States.
Data from the Prescription Drug Atlas (Express
Scripts 2001) show that for some drugs,
regional preferences in use can vary by several-
fold. This means that for highly populated
metropolitan areas with use of a particular drug
exceeding that expected by a normal distribu-
tion, the EEC could be higher than predicted.
This problem is further compounded by the
fact that calculation of the EEC does not take
into consideration cumulative exposure to
drugs sharing the same MOA—where the risk
from a drug’s nontarget effects does not exist in
isolation but should at least be considered in
the context of all drugs of like MOA. The cal-
culation of EECs could be yielding underesti-
mates also because of the expanding purchase
and use of drugs from the gray and black mar-
kets, in large part via the Internet. These use
figures cannot currently be accounted for in
environmental assessments.
Dispensing and expiry. The disposal of
drugs is necessitated by two major factors:
a) excess inventory of nonexpired drugs (i.e.,
unwanted, unneeded but still usable drugs)
and b) outdated drugs [those whose expira-
tion (expiry) dates have been exceeded].
Minimizing the need to dispose as a result of
these two factors can be addressed by mini-
mizing inventory (by pharmacies and con-
sumers alike) and by ensuring that expiration
dates are based on actual, empirical data
rather than projections. The issue of expiry is
not as simple as it may seem because there are
a number of issues involved with setting the
time periods for which a drug can be safely
maintained (and these differ for factory-
dispensed vs. consumer-dispensed forms). In
practice, the time periods for shelf lives are
determined not entirely empirically but also
by estimates and projections. Shelf life is
important as it dictates whether a therapeutic
dose of the active ingredient is still present
and whether degradation products with
adverse therapeutic outcomes are absent.
Conservative dispensed amounts. The
need for disposal could be lessened by reduc-
ing prescribed/purchased quantities too great
to be used before expiration or increasing shelf
life. Reasonable, minimal quantities of med-
ication could be purchased or prescribed until
the effects of the medication and its therapeu-
tic effectiveness are understood by both the
physician and patient. Overprescription of
quantity (or frequent change in medication
type) is a major reason for accumulation of
unused drugs by geriatric patients (Daughton
2003). Consideration should be given to not
penalizing consumers for small-quantity pack-
age sizes. This recommendation, however,
runs counter to mail-order dispensing busi-
nesses run by insurers, where multimonth sup-
plies are favored because of short-term cost
considerations.
Re-engineering of dispensing. A reengi-
neering of pharmacy practice with respect to
the mechanics of drug dispensing could greatly
reduce drug wastage. Progressing from previ-
ous advancements in dispensing (such as blister
packs, also known as “bingo cards”) and hospi-
tal unit-dose systems to the new generation of
“automated medication dispensing” programs
is demonstrated to have a dramatic impact not
just on waste but also on reducing the hours
required by nurses and caregivers devoted to
mundane chores such as “med passing,” and
on assuring accurate medication distribution.
This has been the case especially in long-term
care facilities where the accumulation of
unused medications may be significant. An
example is given by Saffel (1999). Certain U.S.
states such as Georgia do not allow return of
unused portions of 30-day medication pack-
ages. A shorter 7-day exchange cycle provided
by point-of-use “automated medication dis-
pensing” obviates this problem (e.g., Pyxis
2002). One of the recommendations of Kohn
et al. (2000) is that all hospitals and health care
organizations implement the use of automated
drug-ordering systems.
Science-based expiry dates. Expiry dates
could be investigated to see if they can be
extended to reflect true stability durations.
Scientifically sound protocols need to be
implemented for the public sector to define,
determine, predict, and/or monitor actual
expiration periods for both factory-sealed and
unsealed drugs. There have been very few sci-
entific studies on the chemical stability of
drugs in their formulated states. Guidance for
establishing shelf lives has been developed by
the U.S. FDA (2001). The signiﬁcant point,
however, is that there is no requirement to
establish the maximum shelf life for a drug
product—only to establish a documented
shelf life. The major study, still ongoing, for
determining shelf lives is the Shelf Life
Extension Program (SLEP) (JRCAB 2002), a
stability testing program administered by the
U.S. FDA for the U.S. Department of
Defense (for noncivilian purposes). The SLEP
has documented that the actual shelf lives for
some drug formulations exceed the times dic-
tated by the labeled expiration dates (under
ideal storage conditions). The cost savings in
being able to increase the life-cycle times for
drug restocking purportedly claimed by the
Department of Defense have been substantial.
The SLEP program has been highlighted
by the American Medical Association (AMA)
Council on Scientific Affairs as the type of
study requiring expansion (AMA 2001). The
AMA emphasizes, however, that 
expiration dates only apply when the drug product
is stored under defined conditions. Regardless of
the feasibility of extending expiration dates, this
strategy applies only to the date of packaging in the
original factory container. For most U.S. drug
products, expiration dating ranges from 12 to 60
months from the time of original manufacture. . . .
Once the manufacturer’s container is opened and
drug product is transferred to another container for
dispensing or repackaging, the expiration date no
longer applies. The USP has developed recommen-
dations for pharmacists to place a “beyond-use”
date on the label of the new container. There is lit-
tle scientific basis for “beyond-use” dates.
However, the American Pharmaceutical
Association (APhA) encourages, and 17 states
require, that pharmacists place a “beyond-use” date
on the label of the prescription container that is
dispensed to the patient. (AMA 2001) 
For more detailed information, see Okeke
(2002).
Once the pharmacist transfers the drug to
a consumer-use container (including, some-
times, heat-sealed blister packs), an expiration
date is applied (usually 1 year from date of
sale) not based on science; a USP standard for
blister packs is 6 months or one-quarter of the
manufacturer’s original date [Oklahoma State
University (OSU) 2000a, 2000b]. Thus it
would be beneficial when marketing larger-
unit, bulk drugs (e.g., those purchased by
consumers in membership “club” warehouses)
that the bulk container comprise a number of
smaller, factory-sealed packages so as to
extend the usable life. An article in the
Medical Letter (Abramowicz 2002) surmises
that most medications stored in their original,
unopened packaging under proper conditions
retain 70–80% of their potency for at least 10
years. Once removed from original packaging,
most tablets and capsules (dry-formulated
drugs) retain 70–80% of their potency (in
low humidity—i.e., preferably not in a humid
bathroom, which is where most “medicine
cabinets” reside) for 1–2 years after the expi-
ration date. Note, however, that these points
do not address the issue of consumer safety
(e.g., changes in formulation quality) but
rather point to the fact that chemical stability
of the parent drug can be much longer than
implied by expiration dates.
Reduce/phase out controversial uses of
drugs. Historically, drugs or drug classes
often undergo expanded use beyond their
original targeted purposes; this usually results
from off-label prescribing. With certain other
drugs or classes, the original intended use
may have seemed logical at one time—only
to be challenged later as unforeseen conse-
quences emerged (as the known risk–benefit
equation changed). Respective examples of
both scenarios are the postmenopausal use of
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(HRT) and subtherapeutic antibiotics in ani-
mal feed for growth promotion.
HRT’s use to prevent cardiovascular dis-
ease has long proved contentious. The long
presumed benefits of combination HRT
recently have been called into question by a
number of studies, one of which is the 15-
year Women’s Health Initiative (WHI) spon-
sored by the National Institutes of Health’s
National Heart, Lung, and Blood Institute
(see various published papers and links pro-
vided at NHLBI 2002). The WHI study set
out to examine the presumed long-term bene-
ﬁcial effects of combination HRT (involving
estrogen and progestin) on the prevention of
heart disease and hip fractures, but the study
was terminated early when HRT was found
instead to increase a woman’s risk of breast
cancer, heart attack, stroke, and blood clots;
the study did ﬁnd that HRT reduced the risk
of colorectal cancer and bone fractures.
The long-running debates regarding the use
of subtherapeutic antibiotics and of anabolic
steroids in animal feed have resulted in a num-
ber of actions in certain countries to reduce or
abolish their use. An example is the National
Antimicrobial Resistance Monitoring System, a
joint nationwide monitoring program of
the FDA, CDC, and U.S. Department of
Agriculture for detecting the extent and trends
in both human and animal enteric bacteria sus-
ceptibilities to 17 antimicrobial drugs (CVM
2002; also see links at Daughton/U.S. EPA
2002f, 2002i). From time to time, other drugs
develop notoriety as a result of excessive or pro-
found ADRs or other problems (thalidomide’s
original use is a classic example).
Vigilance and ongoing expedited review
of the expansive literature (not limited solely
to the various fields of medicine and health
care but also including the biologic and eco-
logic literature) coupled with reasoned debate
are important responsibilities of science for
detecting possible future problems with
respect to the use of new drugs and the con-
tinued use of established drugs, especially for
those that provide nonessential beneﬁts. The
soundness of current approaches used for
determining whether drugs should be used for
purposes never originally intended might ben-
eﬁt from continual reevaluation.
Supplementary and updated materials for
this mini-monograph are available at the Green
Pharmacy web page (Daughton/U.S. EPA
2003b).
Conclusions
The need for life-cycle stewardship of PPCPs
is driven partly by the growing importance
of preserving freshwater resources coupled
with a water treatment and distribution
infrastructure in need of major maintenance,
repair, and upgrading. “Cradle-to-cradle”
stewardship is prudent not just as a deriva-
tive of the precautionary principle and the
concept of environmental surprise but also
because it holds the potential for major col-
lateral benefits to consumer health care. In
fact, parallels exist between human health
care and the health of ecology. The options
available for minimizing or preventing the
release of PPCPs to the environment reside
in a multitude of components composing
the manufacturing and service sectors of the
health care system—including everything
from drug design, drug delivery, prescribing,
dispensing, individualization of therapy,
packaging, advertising, marketing, education
for health care practitioners, and establish-
ment of real-time PPCP use databases,
among many others. Regardless of the conse-
quences of the current generation of PPCPs
that continually make their way to the envi-
ronment and add to the overall pollutant
burden and play a role in exposed organisms’
4Ts (toxicant–totality–tolerance–trajectory),
we now have the knowledge and the oppor-
tunity to more thoroughly consider the
potential for ecologic or human health
effects from new classes of drugs with unique
mechanisms of biologic action and to begin
setting in place mechanisms for minimizing
their introduction to the environment.
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